Cantor Fitzgerald restated their buy rating on shares of Radius Health, Inc. (NASDAQ:RDUS) in a report released on Friday, November 3rd. Cantor Fitzgerald currently has a $58.00 price target on the biopharmaceutical company’s stock.
Several other brokerages have also issued reports on RDUS. BidaskClub lowered shares of Radius Health from a buy rating to a hold rating in a research note on Tuesday, July 11th. Canaccord Genuity set a $85.00 price objective on shares of Radius Health and gave the company a buy rating in a research report on Monday, July 17th. Zacks Investment Research raised shares of Radius Health from a sell rating to a hold rating in a report on Tuesday, August 8th. Maxim Group reaffirmed a positive rating on shares of Radius Health in a report on Friday, September 29th. They noted that the move was a valuation call. Finally, Goldman Sachs Group, Inc. (The) reissued a neutral rating and issued a $45.00 price objective on shares of Radius Health in a report on Friday, October 6th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company. Radius Health has an average rating of Hold and an average price target of $51.00.
Shares of Radius Health (RDUS) opened at $26.35 on Friday. Radius Health has a 52 week low of $24.66 and a 52 week high of $55.97. The company has a debt-to-equity ratio of 0.53, a quick ratio of 12.79 and a current ratio of 12.87.
Radius Health (NASDAQ:RDUS) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.03). The business had revenue of $13.50 million for the quarter, compared to the consensus estimate of $6.90 million. During the same quarter in the previous year, the business posted ($1.07) EPS. research analysts expect that Radius Health will post -5.4 earnings per share for the current year.
In related news, VP Brent Hatzis-Schoch bought 1,778 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The shares were acquired at an average cost of $28.09 per share, with a total value of $49,944.02. Following the completion of the purchase, the vice president now directly owns 2,278 shares in the company, valued at $63,989.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Growth N. V. Biotech acquired 150,000 shares of the stock in a transaction on Thursday, September 14th. The shares were acquired at an average price of $33.45 per share, for a total transaction of $5,017,500.00. Following the acquisition, the insider now owns 5,448,799 shares of the company’s stock, valued at approximately $182,262,326.55. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 367,678 shares of company stock worth $12,271,498. Insiders own 15.00% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. State of Wisconsin Investment Board purchased a new stake in shares of Radius Health in the second quarter valued at about $1,176,000. Vanguard Group Inc. increased its holdings in Radius Health by 4.5% during the second quarter. Vanguard Group Inc. now owns 3,145,717 shares of the biopharmaceutical company’s stock worth $142,281,000 after buying an additional 135,071 shares during the last quarter. State Street Corp increased its holdings in Radius Health by 12.9% during the second quarter. State Street Corp now owns 1,867,531 shares of the biopharmaceutical company’s stock worth $84,473,000 after buying an additional 213,399 shares during the last quarter. BlackRock Inc. increased its holdings in Radius Health by 10.0% during the second quarter. BlackRock Inc. now owns 2,893,641 shares of the biopharmaceutical company’s stock worth $130,881,000 after buying an additional 262,896 shares during the last quarter. Finally, TimesSquare Capital Management LLC bought a new position in Radius Health during the second quarter worth about $25,589,000.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.